Phellinus linteus: Korea's Most Prized Medicinal Mushroom

Meshima (Phellinus linteus)

96.7% tumour inhibition, 1968

A Japanese screening programme reported that a hot-water extract of Phellinus linteus inhibited Sarcoma 180 growth by 96.7% — the strongest result among the basidiomycetes tested. That 1968 finding launched five decades of research. Human evidence arrived only in 2022, and it is narrower than the marketing suggests.

Ikekawa et al., Gann, 1968; Sliva, Exp Ther Med, 2010

1 endpoint

reached statistical significance across both 2022 CONSORT trials — NK cell activity in the 98-person study, from the same research group that ran the other

Hispolon

a phenolic compound characteristic of Phellinus and close relatives, with anti-cancer mechanisms documented in cell lines but never tested in humans

Wrong species

the sanghuang cultivars formally registered in Korea group with Sanghuangporus sanghuang, not with the Phellinus linteus the research was done on (Han et al., 2016)

Ikekawa et al., Gann, 1968; Sliva, Exp Ther Med, 2010

View as image ↗

Phellinus linteus is the medicinal mushroom that researchers in Korea and Japan studied for decades while most of the Western supplement industry looked elsewhere. Known as sangwhang in Korea, meshimakobu in Japan and sanghuang in China, it grows as a bracket fungus on mulberry trees and carries a long history in East Asian medical traditions. A 2023 systematic review identified antitumour, immunomodulatory, anti-inflammatory, antioxidant and antidiabetic activities across its polysaccharide compounds.^[6] Two CONSORT-compliant randomised trials published in 2022 make it one of the few Phellinus species with any published human clinical data at all.

That is the case for paying attention. This article makes it, and then does something most coverage of this mushroom does not: it separates the parts of the story that hold up from the parts that have drifted. Several of the most-repeated meshima claims — including the one you will find in the first paragraph of almost every article on the species — do not survive contact with the papers they cite. For the complete scientific overview including mechanisms and clinical evidence in depth, the full guide to meshima mushroom covers it comprehensively.

Why Western Readers Rarely Encounter Meshima

The gap between Phellinus linteus's research standing and its name recognition in Western markets is largely a function of geography and language rather than evidence quality.

In Korea, sangwhang sits within the formal hanbang pharmacopeia and is among the most expensive medicinal materials sold. In Japan, meshimakobu trades as a premium health product with a substantial domestic market. Much of the research on this species was conducted at Korean and Japanese institutions and published in Korean, Japanese and, increasingly, English-language journals — but marketing to Western consumers lagged well behind the science.

The 2023 systematic review by Qin and colleagues indicates the current research depth.^[6] Published in the International Journal of Biological Macromolecules, it reviewed extraction methods, structural characterisation and biological functions of Phellinus linteus polysaccharides specifically — not across multiple species, but within this single mushroom's compound class. That a species supports a dedicated structural review of one compound class reflects a body of primary research few medicinal mushrooms have accumulated.

What Phellinus linteus lacks is the Western marketing apparatus that surrounds lion's mane (Hericium erinaceus) or turkey tail (Trametes versicolor). Lion's mane is associated with nerve growth factor promotion and cognitive support. Turkey tail is associated with PSK, an approved cancer adjunct in Japan. Phellinus linteus has a different mechanistic profile, but fewer Western brands built product lines around it, so fewer Western consumers searched for it.

The awareness gap is real. It is worth separating from a second gap, which the marketing has quietly filled in.

Fact Check

The claim that made meshima famous

The claim

“Phellinus linteus had the highest antitumour inhibition rate of approximately 600 mushrooms tested.”

Repeated across supplement pages, retail listings and health articles, usually attributed to a 2010 review.

What research shows

Unsupported

The 1968 Japanese screening it descends from reported 96.7% inhibition of Sarcoma 180 by a hot-water extract of P. linteus — the strongest of the basidiomycetes tested. That result is real and it is impressive.

The figure of 600 appears in neither the 1968 paper nor the 2010 review that restates it. The review says only that "an original study in Japan demonstrated that PL has the strongest antitumor effects compared to other mushrooms." The screening was also in mice, against a transplanted sarcoma line, more than half a century ago.

Ikekawa et al., Gann, 1968 (PMID 5723060); Sliva, Exp Ther Med, 2010 [3]

The Species Identity Problem: What to Know Before Buying

The species question is an honest complication that every serious resource on Phellinus linteus should address, and most render it too gently.

Han and colleagues published a 2016 phylogenetic analysis examining the identity of "sanghuang" as used in Korea.^[5] They sequenced ITS nuclear ribosomal DNA from 74 strains spanning the Phellinus linteus–baumii complex, including the parental strains of the sanghuang varieties formally registered with the Korea Seed & Variety Service. Those registered strains — ASI 26046 (Corea sanghuang), ASI 26114 (Boolro) and ASI 26115 (HK 1-ho) — grouped with Sanghuangporus sanghuang, not with Phellinus linteus.

That is a sharper finding than the usual "products may contain several Phellinus species." The cultivars Korea formally registers and grows are, phylogenetically, a different organism from the one the Korean research programme publishes under.

What Han et al. 2016 actually found

The Sanghuang Sold in Korea Is Not the Mushroom in the Research

The usual framing — “products may contain several Phellinus species” — understates the problem. A phylogeny of 74 strains found that the parental strains of the sanghuang varieties formally registered with the Korea Seed & Variety Service group with Sanghuangporus sanghuang, not with Phellinus linteus. [5]

Material used in the published P. linteus studies

Authenticated research strains, 1968 onward

Matches the studied organism

Phellinus linteus sensu stricto — now often placed as Tropicoporus linteus

This is the organism every efficacy finding in this article refers to, including both 2022 trials.

Korean registered sanghuang cultivars

ASI 26046 (Corea sanghuang), ASI 26114 (Boolro), ASI 26115 (HK 1-ho)

Different organism from the research

Grouped with Sanghuangporus sanghuang in the 74-strain ITS phylogeny

The cultivars formally registered and cultivated in Korea are not P. linteus, even though the Korean research programme is published under that name.

Chinese "sanghuang" (桑黄) trade material

Traditional term, mulberry-associated

Cannot be resolved from the label

Sanghuangporus — a genus in which 13 species are now recognised

A shared traditional category, not a species. Which of the 13 is in a given product is not recoverable from the name.

A supplement labelled only "Phellinus linteus"

The most common label in Western retail

Cannot be resolved from the label

Unverifiable without sequencing or a named strain

Tells you which literature the seller is pointing at. Does not tell you which species was grown.

Why this is not a pedantic taxonomy point

Every efficacy claim on this page — the 1968 screening result, the hispolon mechanisms, the two 2022 trials — was generated on authenticated Phellinus linteus material. If the jar in front of you contains Sanghuangporus sanghuang, the evidence on this page was not generated on what you are taking. The two organisms are related and share compound classes, but no trial has tested whether the findings transfer.

Genus placement is still in flux across treatments; Phellinus linteus, Tropicoporus linteus and Sanghuangporus spp. all appear in current literature for organisms in this complex. The practical takeaway is unchanged: a binomial alone does not identify the material, and a named, sequenced strain does.

Phylogeny from ref [5]; genus context from Zhu et al., Front. Microbiol., 2019

A second complication runs alongside it. Taxonomic revision has moved much of this group out of Phellinus altogether: species have been recombined into Sanghuangporus, and the meshima of the research literature is now often placed in Tropicoporus as T. linteus. Sanghuangporus is a genuine genus in which 13 species are currently recognised, so a product labelled "Sanghuangporus sanghuang" is not interchangeable with one labelled "Phellinus linteus," and neither name on its own tells you what was grown.

Two Compound Classes That Make Meshima Structurally Different

What separates Phellinus linteus from most other medicinal mushrooms is the presence of two mechanistically distinct compound classes operating through different pathways.

The first is polysaccharides — beta-glucan-backbone compounds with characteristic branching that activate immune function and suppress inflammatory signalling. Qin and colleagues documented these mechanisms across antitumour, immunomodulatory and anti-inflammatory activity in the most comprehensive structural analysis available.^[6] Macrophage activation, NF-κB suppression and T cell modulation are shared with other medicinal mushrooms to varying degrees.

The second is hispolon, a polyphenolic compound characteristic of Phellinus and closely related fungi and largely absent from the species that dominate Western markets. Its mechanisms have been mapped in some detail. Chen and colleagues showed hispolon arresting cells at G0/G1 and triggering both extrinsic and intrinsic apoptotic pathways in a human leukaemia line, with caspase-3, -8 and -9 cleavage and a shifted Bax/Bcl-2 ratio.^[7] Kim and colleagues showed it sensitising cancer cells to TRAIL — a pro-apoptotic signal many tumours resist — by upregulating death receptors through CHOP.^[8]

These effects operate at the tumour cell level rather than through immune modulation, which means Phellinus linteus carries two independent candidate mechanisms where most mushrooms carry one. The important qualifier: all of it is cell-line work. Hispolon has never been given to a human being in a published trial.

Sliva and colleagues provided the most-cited extract-level study.^[4] In highly invasive MDA-MB-231 breast cancer cells, Phellinus linteus extract inhibited proliferation and colony formation through S-phase arrest and upregulation of p27^Kip1; suppressed adhesion, migration and invasion by reducing secretion of urokinase-plasminogen activator; and blocked early capillary morphogenesis in endothelial cells by downregulating VEGF secretion. All three effects tracked to inhibition of AKT signalling, with suppressed phosphorylation at Thr308 and Ser473. Growth inhibition, angiogenesis suppression and reduced invasion in one model is the triad researchers consider most clinically suggestive — in cells.

For a detailed breakdown of the compounds and structural characterisation, Phellinus linteus bioactive compounds: polysaccharides and phenols covers the chemistry in full.

The 2022 Clinical Trials: What the Human Data Actually Shows

The most consequential development in Phellinus linteus research is the arrival of human trials in 2022 — and the most consequential misreading of this species concerns what those trials found.

Both were designed to CONSORT standards, the benchmark for randomised trial reporting. Both were published in Medicine (Baltimore). Both were led by Ku Yong Ho and Kang Jae Hui. They are two reports from one research group, not two independent confirmations, and they are frequently miscited — including as to authorship and journal — in coverage of this mushroom.

The larger trial came first, in August 2022. Ku, Kang and Lee randomised 98 participants to 1,000 mg/day of Phellinus linteus extract or matched dextrin placebo for eight weeks. The primary endpoint, natural killer cell activity, increased significantly in the extract group (P < .05). The nine secondary endpoints — TNF-α, IFN-γ, IL-1β, IL-2, IL-6, IL-12, IgG1, IgG2 and IgM — did not reach significance, though the authors noted a tendency toward improvement. No extract-related adverse effects on liver or renal function were observed.^[1]

The second, in October 2022, was explicitly a pilot: 30 participants across three arms of ten, testing 1,000 mg and 2,000 mg daily against placebo for eight weeks. NK cell activity and IL-6 "tended to improve" in the 1,000 mg group; immunoglobulins "did not show significant changes." Its stated conclusion is that evidence to justify a main clinical trial has been secured — the paper asks for the larger study rather than claiming one.^[2]

Endpoint-by-endpoint

What the Two 2022 Trials Actually Measured — and What Reached Significance

Both trials are usually cited together as “two randomised trials confirming immune enhancement.” Laid out endpoint by endpoint, one result reached statistical significance: NK cell activity in the 98-person trial. Every other efficacy endpoint across both papers was a non-significant trend. Note also that these are not independent replications — the same two authors led both, in the same journal, months apart.

The larger trial[1]Ku, Kang & Lee · Medicine (Baltimore) · Aug 2022

98 participants·Randomised, double-blind, placebo-controlled · 8 weeks

1,000 mg/day extract vs. 1,000 mg/day dextrin placebo

NK cell activity (primary endpoint)

Significant

Increased vs. placebo, P < .05 — the only significant efficacy result across both trials

TNF-α, IFN-γ, IL-1β, IL-2, IL-6, IL-12

Trend only

Secondary endpoints; direction favoured extract but did not reach significance

IgG1, IgG2, IgM

Trend only

Secondary endpoints; no significant change reported

Liver and renal safety panels

No change

No extract-related adverse outcomes observed over 8 weeks

The pilot trial[2]Ku & Kang · Medicine (Baltimore) · Oct 2022

30 participants (3 arms of 10)·Randomised, double-blind, placebo-controlled PILOT · 8 weeks

1,000 mg/day or 2,000 mg/day extract vs. 2,000 mg/day dextrin placebo

NK cell activity

Trend only

"Tended to improve" vs. placebo in the 1,000 mg arm — not reported as significant

Interleukin-6

Trend only

"Tended to improve" in the 1,000 mg arm — not reported as significant

IgG1, IgG2, IgM

No change

Authors state these "did not show significant changes"

Safety assessment

No change

No hazards identified in adverse reactions, vital signs, or lab findings

What this does and does not establish

Across 128 participants, one immune marker moved significantly in one trial. That is a real result and it is more human evidence than most medicinal mushrooms have — but it is a single significant biomarker endpoint from a single research group, not a confirmed clinical benefit. Neither trial enrolled cancer patients or measured any cancer outcome. The pilot paper’s own conclusion asks for a larger main trial rather than declaring the question settled.

Endpoints and wording taken from the published abstracts of refs [1] and [2]

Key Study

Ku, Kang & Lee (2022) · Medicine (Baltimore)

Population

98 healthy adults, Korea

Intervention

1,000 mg/day Phellinus linteus extract, 8 weeks

Comparator

1,000 mg/day dextrin placebo, double-blind

Finding

Natural killer cell activity increased significantly versus placebo (P < .05). All nine secondary endpoints — six cytokines and three immunoglobulins — showed non-significant trends. No extract-related liver or renal adverse effects.

preliminary A single significant biomarker endpoint in healthy volunteers, from the same group that ran the companion pilot. Immune-marker change is not a demonstrated clinical benefit, and no cancer outcome was measured.

Ku, Kang & Lee, Medicine (Baltimore), 2022 [1]

Stated plainly: across 128 participants in two trials from one group, one endpoint reached statistical significance. That is meaningfully more human evidence than most medicinal mushrooms carry, and it is considerably less than "clinically proven to boost immunity." Both trials enrolled healthy volunteers, measured immune markers rather than illness, and ran eight weeks. Neither tells us whether anyone got sick less often.

The Anti-Cancer Evidence: What the Preclinical Record Shows

The case for Phellinus linteus in cancer research rests on a preclinical record that is unusually deep and long-running, paired with an honest acknowledgment that it has never been tested against a cancer outcome in a randomised human trial.

The history begins with the 1968 Japanese screening described above, which reported 96.7% inhibition of Sarcoma 180 in mice and pointed decades of mechanistic work at this species. Sliva's 2010 review synthesised that work and documented three independent case reports of tumour regression following Phellinus linteus use: a hormone-refractory prostate cancer with progressive bone metastasis in Japan; hepatocellular carcinoma with a metastatic frontal bone mass in a 65-year-old man in Korea, which regressed after radiotherapy and 18 months of ingestion; and hepatocellular carcinoma with multiple lung metastases in a 79-year-old man, which regressed over six months.^[3]

Case reports are the weakest form of clinical evidence, and these carry a specific confound worth naming: the second patient received radiotherapy alongside the mushroom, and no case report can separate the two contributions. Three regressions with no denominator also tell us nothing about how many people took Phellinus linteus and saw nothing happen.

One study sits between the case reports and the absent trials. Lee and colleagues analysed 217 patients who underwent curative resection for pancreatic ductal adenocarcinoma, using propensity score matching.^[9] Phellinus linteus use was the only significant predictor of completing adjuvant chemotherapy (P = .039), and disease-free and overall survival were higher in the group that used it. The authors' interpretation is careful and worth preserving: the plausible mechanism is improved tolerance of chemotherapy leading to better adherence, not direct antitumour action. It is retrospective and observational, so patients well enough to take a supplement may simply have been patients well enough to finish chemotherapy.

Evidence Review

1. Cell studiescompleted

   Polysaccharide immune activation and hispolon-driven cell-cycle arrest, apoptosis and TRAIL sensitisation, characterised across five decades [6][7][8]

2. Animal modelscompleted

   From the 1968 Sarcoma 180 screening onward; extract-level antitumour, anti-angiogenic and anti-invasive effects in rodent and cell models [3][4]

3. Case reportscompleted

   Three independent reports of tumour regression reviewed in 2010 — one following radiotherapy, which the case cannot disentangle — plus one retrospective propensity-matched analysis of chemotherapy adherence [3][9]

4. Small human trialscurrent

   Two 2022 CONSORT trials in 128 healthy volunteers from a single Korean research group; one endpoint reached significance — NK cell activity in the 98-person study [1][2]

5. Randomised trials in patientsmissing

   No randomised trial has enrolled cancer patients or measured a cancer outcome. The 2022 pilot exists to justify a larger immune trial that has not yet reported

6. Meta-analysis / replicationmissing

   No independent group has replicated the 2022 immune findings, and there is no pooled clinical analysis to draw on

Phellinus linteus has one of the deeper preclinical profiles in the medicinal mushroom literature and among the thinnest human clinical records that still counts as non-empty. The honest position is that mechanism and animal work are strong, first human evidence exists and is narrow, and the clinical question is open rather than answered.

Refs [1]–[4], [6]–[9]; Ikekawa et al., Gann, 1968

For a full examination of how this compares to turkey tail and other species, meshima vs. other anti-cancer mushrooms covers that comparison directly.

What the Research Does Not Cover: Safety and Interactions

Discussion of meshima tends to stop at efficacy. Two safety signals deserve more prominence than they usually get, particularly given who reaches for this mushroom.

Safety

Moderate

Immune stimulation is not universally desirable

Concern

A published case report documents exacerbation of pemphigus — an autoimmune blistering disorder — following Phellinus linteus ingestion. The mechanism that makes the mushroom interesting, immune activation, is the same mechanism that can aggravate a condition driven by immune activity. Memorial Sloan Kettering's monograph lists this among its adverse-effect entries.

What the research says

No trial has assessed Phellinus linteus in people with autoimmune disease, and both 2022 trials enrolled healthy volunteers only. The absence of adverse findings in those trials says nothing about this population.

Particularly relevant for: People with autoimmune conditions, transplant recipients, and anyone on immunosuppressive therapy

What to do

Discuss with the clinician managing the condition before use. Do not treat 'no adverse events in healthy volunteers' as reassurance for an immune-mediated illness.

Jin et al., J Eur Acad Dermatol Venereol, 2011 (PMID 20561124); MSK Integrative Medicine monograph

Safety

Moderate

A plausible drug-interaction route that has never been tested in people

Concern

Polysaccharides from Phellinus linteus broth and mycelia inhibited cytochrome P450 isozymes CYP1A1, CYP1A2, CYP2B1 and CYP2E1 in rat liver microsomes across the concentrations tested. CYP enzymes clear a large share of prescription drugs, including several chemotherapy agents. Inhibiting them can raise drug exposure.

What the research says

This is rat microsome data, not a human pharmacokinetic study, and it cannot be converted into a dose or a predicted interaction. No human interaction study for Phellinus linteus has been published. That makes the risk unquantified rather than absent — which matters most for the cancer patients most likely to take it alongside active treatment.

Particularly relevant for: Anyone taking prescription medication, and especially anyone undergoing chemotherapy

What to do

Disclose supplement use to the treating oncologist or pharmacist, who can check the specific regimen for CYP-dependent agents.

Shon et al., Biotechnology Letters, 2003 (PMID 12882294)

Nothing in this article is medical advice, and none of it should be used to make a treatment decision. Phellinus linteus is not an approved therapy for cancer or any other disease in any major jurisdiction. Memorial Sloan Kettering's own assessment of the evidence is that studies in humans are very limited and that well-designed trials are needed to confirm the effects observed in the laboratory. Anyone considering it during cancer treatment should raise it with their oncology team first.

Why the Research Community Is Paying Attention

Strip out the overstatement and a genuinely interesting picture remains.

A species does not receive a dedicated systematic review of its polysaccharide compound class in the International Journal of Biological Macromolecules without a substantial body of primary research behind it.^[6] The 2022 trials, whatever their limits, moved this mushroom from a purely preclinical evidence base to one with a human foothold — a threshold most medicinal mushrooms have not crossed. Memorial Sloan Kettering maintains a Phellinus linteus monograph, reflecting an oncology-institution awareness that most Western consumer resources have not matched.

Claim → Source → What the source says

Five Meshima Sentences, Traced Back to Their Sources

Each of these sentences is repeated across product pages and health articles, and each one descends from a real document. Reading left to right shows where the sentence and the document diverge. None of these corrections argue that meshima is uninteresting — they argue that the real record is more specific, and more limited, than the marketing version.

“Highest antitumour rate of roughly 600 mushrooms tested”

Not in the source

Ikekawa et al., Gann, 1968; restated in ref [3]

The 1968 screening reported 96.7% inhibition of Sarcoma 180 by a hot-water extract — the strongest of the basidiomycetes tested. No count of 600 species appears in the primary paper or in the review that restates it, which says only "the strongest antitumor effects compared to other mushrooms."

“Clinically proven to boost immunity”

Overstated

Refs [1] and [2]

One endpoint reached significance: NK cell activity in the 98-person trial (P < .05). Cytokines and immunoglobulins showed non-significant trends. Both trials were in healthy volunteers and came from the same research group.

“A proven anti-cancer mushroom”

Not in the source

Refs [3], [4], [7], [8], [9]

No randomised trial has tested P. linteus against a cancer outcome in humans. The record is cell-line and animal work, three case reports of tumour regression (one following radiotherapy), and one retrospective observational analysis of treatment adherence.

“Grows only on aged mulberry trees”

Real, with limits

Traditional description; MSK Integrative Medicine monograph

The mulberry association is genuine and gives the mushroom its Korean and Chinese name — sanghuang, "mulberry yellow." The exclusivity and the specific age of the host tree are trade embellishments rather than documented constraints.

“2,000 years of documented medicinal use”

Overstated

Repeated in commerce; no primary citation attached

Long-standing use in Korean, Japanese and Chinese medical traditions is not in dispute. The precise round figure travels without a primary documentary source and is not something the research literature establishes.

Traced against refs [1]–[4] and [7]–[9], plus Ikekawa et al., Gann, 1968

What this amounts to: Phellinus linteus has real research depth, a culturally central history in Korean and Japanese medicine, and a compound profile that is mechanistically differentiated from the more widely marketed species. Its low Western profile reflects a communication gap. The correction this article makes is that the communication gap has been filled, in the meantime, with claims that outrun the record — and that a species with this much genuine research behind it does not need them.

For the full history in Korean traditional medicine, the history of meshima in Korean traditional medicine covers that record in depth. For how Phellinus linteus fits into the broader immune mechanism picture alongside cordyceps and related species, the cross-species immune evidence tells a connected story.

The Bottom Line

Phellinus linteus (meshima/sangwhang) pairs a long tradition of use in East Asian medicine with a research record that starts from a striking 1968 result — 96.7% inhibition of Sarcoma 180, the strongest of the basidiomycetes screened — and runs through five decades of mechanistic work to a 2023 systematic review of its polysaccharides. Human evidence arrived in 2022 as two CONSORT trials, but they came from a single Korean research group rather than two independent teams, and across 128 participants exactly one endpoint reached significance: NK cell activity in the larger study. Its anti-cancer evidence remains preclinical; the human oncology record is three case reports and one retrospective observational analysis of chemotherapy adherence. Two safety signals get too little attention — a case report of pemphigus exacerbation, and CYP450 inhibition in rat microsomes that has never been characterised in people. And species identity is a live problem: the sanghuang cultivars formally registered in Korea group with Sanghuangporus sanghuang, not with the Phellinus linteus the research was done on.

Frequently Asked Questions

Why is Phellinus linteus so important in Korea?

Phellinus linteus (sangwhang) is among the most prized and expensive medicinal materials in Korean hanbang practice, with long-standing traditional use for immune support. Its modern reputation traces to a 1968 Japanese screening study reporting that a hot-water extract inhibited Sarcoma 180 growth by 96.7%, the strongest result among the basidiomycetes tested — a finding that directed decades of research at this species. Two CONSORT-randomised trials in 2022 added the first human clinical data. One caveat is worth carrying: research conducted under the Phellinus linteus name may not correspond to the sanghuang cultivars now registered and grown in Korea, which group with a related species (Han et al., 2016).

What makes meshima the most prized mushroom in Korea?

Historical prestige, scarcity and research attention combined. It is associated with mulberry trees — the Korean and Chinese name sanghuang means "mulberry yellow" — and wild material is rare and costly, though claims that it grows exclusively on aged mulberry are trade embellishment rather than documented fact. It contains hispolon, a phenolic compound characteristic of Phellinus and close relatives, with cell-cycle arrest, apoptosis and TRAIL-sensitisation activity documented in cancer cell lines (Chen et al., 2013; Kim et al., 2016). The 2023 Qin systematic review confirmed activity across antitumour, immunomodulatory, anti-inflammatory, antioxidant and antidiabetic pathways at the polysaccharide level.

Is Phellinus linteus used in Korean cancer treatment?

It is used in Korean integrative medicine alongside conventional treatment, but it is not an approved cancer therapy anywhere and no randomised trial has tested it against a cancer outcome. The human oncology record consists of three case reports of tumour regression reviewed by Sliva in 2010 — one of which followed radiotherapy, which the case cannot separate from the mushroom — and one retrospective propensity-matched analysis of 217 pancreatic cancer patients in which Phellinus linteus use predicted completion of adjuvant chemotherapy (Lee et al., 2019). The authors of that analysis attribute the effect to better treatment tolerance and adherence, not direct antitumour action. The preclinical work, including the Sliva 2008 breast cancer study showing growth, angiogenesis and invasion inhibition via AKT, is cell-line and animal evidence.

What is the scientific evidence for Korean sangwhang mushroom?

In order of strength: (1) Two CONSORT-randomised trials from 2022, both led by Ku and Kang in Medicine (Baltimore), totalling 128 healthy participants — NK cell activity rose significantly in the 98-person trial (P < .05), while all other endpoints across both trials showed non-significant trends; (2) A 2023 systematic review of polysaccharide compounds confirming antitumour, immunomodulatory, anti-inflammatory, antioxidant and antidiabetic activities (Qin et al., 2023); (3) Cell-line studies of hispolon mechanisms including G0/G1 arrest, caspase-mediated apoptosis and TRAIL sensitisation; (4) Extract-level anti-cancer work such as the AKT-pathway breast cancer study (Sliva et al., 2008); (5) Three case reports of tumour regression and one retrospective observational study in cancer patients. No randomised human cancer outcome trial exists, and the 2022 findings have not been independently replicated.

How do Koreans use meshima mushroom?

In hanbang, sangwhang is most often prepared as a decoction — dried material simmered in water for extended periods to extract polysaccharides. It is also sold as powder in capsules and as alcohol extracts, which capture phenolic compounds including hispolon. The 2022 trials used standardised extracts at 1,000 mg or 2,000 mg per day for eight weeks rather than traditional preparations, so traditional decoctions have not been clinically tested. Han and colleagues' 2016 work is directly relevant here: traditional and commercial Korean sanghuang may be a different species from the authenticated Phellinus linteus the research used, so buyers who want the researched organism should look for a current binomial plus a named, sequenced strain. This is general information, not medical advice — anyone considering use during cancer treatment or with an autoimmune condition should consult their clinician first.

Sources & References

1. 1RTHM-01556·Ku, Yong Ho et al. (2022). “Effects of Phellinus linteus extract on immunity improvement: A CONSORT-randomized, double-blinded, placebo-controlled trial..” Medicine.Study breakdown →PubMed →↩
2. 2RTHM-01555·Ku, Yong Ho et al. (2022). “Efficacy of Phellinus linteus extract on immunity enhancement: A CONSORT-randomized, double-blind, placebo-controlled pilot trial..” Medicine.Study breakdown →PubMed →↩
3. 3RTHM-00364·Sliva, Daniel (2010). “Medicinal mushroom Phellinus linteus as an alternative cancer therapy..” Experimental and therapeutic medicine.Study breakdown →PubMed →↩
4. 4RTHM-00271·Sliva, D et al. (2008). “Phellinus linteus Extract in Breast-Cancer Cell Models: What This 2008 Study Actually Found.” British journal of cancer.Study breakdown →PubMed →↩
5. 5RTHM-00783·Han, Jae-Gu et al. (2016). “Species identity of Phellinus linteus (sanghuang) extensively used as a medicinal mushroom in Korea..” Journal of microbiology (Seoul.Study breakdown →PubMed →↩
6. 6RTHM-01770·Qin, Dandan et al. (2023). “Polysaccharides from Phellinus linteus: A systematic review of their extractions, purifications, structures and functions..” International journal of biological macromolecules.Study breakdown →PubMed →↩
7. 7RTHM-00514·Chen, Yi-Chuan et al. (2013). “Hispolon from Phellinus linteus induces G0/G1 cell cycle arrest and apoptosis in NB4 human leukaemia cells..” The American journal of Chinese medicine.Study breakdown →PubMed →↩
8. 8RTHM-00792·Kim, Ji-Hun et al. (2016). “Hispolon from Phellinus linteus induces apoptosis and sensitizes human cancer cells to the tumor necrosis factor-related apoptosis-inducing ligand through upregulation of death receptors..” Oncology reports.Study breakdown →PubMed →↩
9. 9RTHM-01082·Lee, Sung Hwan et al. (2019). “Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score-Matched Analysis..” Integrative cancer therapies.Study breakdown →PubMed →↩